Edobacomab

N/A

Report date: 2023/04/25 14:52:27

Base Information

Drug NameEdobacomab
Drug Alias Name埃巴单抗E5Xomen-E5奈巴库单抗Septomonab +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionLipid modulators
TargetsLipid
Therapy Area/IndicationsDepressionInflammationMyelodysplastic Syndromes +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer IncXoma Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles
Inactive CompaniesRadboud University Medical CenterWashington University School Of MedicineNational Cancer Institute +[4] 
Active IndicationsDepressionAnhedonia
Inactive IndicationsInflammationMyelodysplastic SyndromesLymphoma, Non-Hodgkin +[9] 

Other Information

ATC CodeN/A
Related LinksWikipedia